Shares of Lyra Therapeutics Inc. soared more than 310% on data from its second phase III trial testing drug-device candidate LYR-210 in patients with chronic rhinosinusitis, with results from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results